164 results
8-K
ACST
Acasti Pharma Inc.
25 Sep 24
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
8:00am
-ON safety trial has completed enrollment. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01
8-K
EX-99.1
ACST
Acasti Pharma Inc.
25 Sep 24
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
8:00am
Exhibit 99.1
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
Data Readout Expected Early … Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405). The STRIVE-ON trial is a prospective, open-label, randomized (1:1 ratio), parallel
8-K
EX-99.1
ACST
Acasti Pharma Inc.
9 Aug 24
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
8:00am
Phase 3 STRIVE-ON Safety Trial of GTX-104
Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025 … and participating clinical trial sites, we surpassed the 50% enrollment milestone in our Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405),” said
424B3
ACST
Acasti Pharma Inc.
7 Aug 24
Prospectus supplement
4:14pm
indication or could be repurposed for use in new indications.
The existing well understood efficacy and safety profiles of these marketed compounds … ), if sufficient support of a product’s safety and efficacy either through previous U.S. Food and Drug Administration (“FDA”) experience or sufficiently
8-K
xqh9956wg ecud8nlf
27 Jun 24
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
4:10pm
8-K
EX-99.1
o7xd8u7
27 Jun 24
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
4:10pm
8-K
EX-99.1
x7xe5km
21 Jun 24
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
8:00am
8-K
EX-99.1
kojp4ycwk
1 Apr 24
Regulation FD Disclosure
8:00am
8-K
EX-99.1
6c7gtb
12 Feb 24
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
8:00am
8-K
EX-99.1
m6e1 9ofess0tj57e
13 Nov 23
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
12:00am
8-K
EX-99.1
vvukd ifyb42z815z1
23 Oct 23
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
4:30pm
424B3
1oi 46b5t
16 Oct 23
Prospectus supplement
4:31pm
8-K
EX-10.1
rnf96
26 Sep 23
Acasti Announces $7.5 Million Private Placement Equity Financing
8:10am